Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference

Rhea-AI Summary

Akcea Therapeutics (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals (NASDAQ:IONS), will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference on June 23, 2020, at 3:30 p.m. ET. CEO Damien McDevitt and CCO Kyle Jenne will represent the company in this virtual event. Participants can access the live webcast through Akcea's website.
Akcea focuses on developing drugs for serious and rare diseases, including TEGSEDI and WAYLIVRA, leveraging Ionis' proprietary technology.

BOSTON, June 17, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt, chief executive officer, and Kyle Jenne, chief commercial officer, will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference, which is being held virtually, on Tuesday, June 23, 2020 at 3:30 p.m. ET.

The above listed date is subject to change. Details on presentation times or changes to presentation dates can be found on the Company's website. Please check www.akceatx.com for the latest information.

A live webcast of the presentation will be available on the "Media & Investors" section of the Akcea website. A replay will be available within 48 hours and will be archived for a limited time.

ABOUT AKCEA THERAPEUTICS
Akcea Therapeutics, Inc., a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), is a biopharmaceutical company focused on developing and commercializing medicines to treat patients with serious and rare diseases. Akcea is commercializing TEGSEDI^® (inotersen) and WAYLIVRA^® (volanesorsen), as well as advancing a mature pipeline of novel medicines, including AKCEA-APO(a)-L_Rx, vupanorsen (AKCEA-ANGPTL3-L_Rx), AKCEA-APOCIII-L_Rx, and AKCEA-TTR-L_Rx, with the potential to treat multiple diseases. All six medicines were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis' proprietary antisense technology. TEGSEDI is approved in the U.S., E.U., Canada and Brazil. WAYLIVRA is approved in the E.U. and is currently in Phase 3 clinical development for the treatment of people with familial partial lipodystrophy, or FPL. Akcea is headquartered in Boston, Massachusetts, and is building the infrastructure to commercialize its medicines globally. Additional information about Akcea is available at -1%26h%3D1677669684%26u%3Dhttps%253A%252F%252Fwww.globenewswire.com%252FTracker%253Fdata%253D98FWYX_s_dA31tMrJirPwqjsNQulvCQnPlZjYhKDXxj1aTAE5AtAayhe5GX4h5t_Fe2YeCvgPjPTm7idyowhOVrLUvs3N9Je_14zHHBsr3F2vIAZo5Z-gdPPRkBzHrOwLYYR4L95VO_RvI-_y1aQOuYphIUge2oBcnT9sk8EBCyWWSoyprUij1kXCXwCpF35Z1DbzUwY6e6xyvMZKgdDsiQA4dKqU0ZI3ar5gczNEUY%253D%26a%3Dwww.akceatx.com&a=www.akceatx.com" rel="nofollow">www.akceatx.com and you can follow the Company on Twitter at @akceatx. 

FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding the business of Akcea Therapeutics, Inc. Any statement describing Akcea's goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of Akcea's medicines in development is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Akcea's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akcea's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Akcea. In particular, we caution you that our forward-looking statements are subject to the ongoing and developing circumstances related to the COVID-19 pandemic, which may have a material adverse effect on our business, operations and future financial results. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Akcea's programs are described in additional detail in Akcea's quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the SEC. Copies of these and other documents are available from the company.

In this press release, unless the context requires otherwise, "Ionis," "Akcea," "Company," "Companies," "we," "our," and "us" refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.

Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc., Akcea Therapeutics®, TEGSEDI® and WAYLIVRA® are trademarks of Akcea Therapeutics, Inc.

View original content to download multimedia:http://www.prnewswire.com/news-releases/akcea-therapeutics-to-present-at-the-bmo-2020-prescriptions-for-success-healthcare-conference-301078216.html

SOURCE Akcea Therapeutics, Inc.

FAQ

What is the date of the Akcea Therapeutics event at the BMO 2020 Conference?

The event will take place on June 23, 2020.

Who will represent Akcea Therapeutics at the BMO 2020 Conference?

CEO Damien McDevitt and CCO Kyle Jenne will represent Akcea.

What time is the Akcea Therapeutics session at the BMO 2020 Conference?

The session is scheduled for 3:30 p.m. ET.

How can I watch the Akcea Therapeutics presentation at the conference?

The presentation will be available via a live webcast on Akcea's website.

What is the focus of Akcea Therapeutics?

Akcea Therapeutics is focused on developing treatments for serious and rare diseases.

What are some products commercialized by Akcea Therapeutics?

Akcea is commercializing TEGSEDI and WAYLIVRA, among others.